Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OWP-104
- Development stage
- Preclinical
- Lead developer
- OWP Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OWP-104 is an investigational oral liquid formulation of an established central nervous system (CNS) drug, currently in preclinical development by OWP Pharmaceuticals for the treatment of psychiatric disorders. Developed using the 505(b)(2) regulatory pathway, OWP-104 aims to provide an alternative oral liquid delivery option for pediatric, adolescent, and other patient populations who have difficulty swallowing solid oral dosage forms. The specific active pharmaceutical ingredient and mechanism of action for OWP-104 have not been publicly disclosed.
Beyond the preview
Go deeper on OWP-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OWP-104.